DK1664050T3 - Neurobeskyttende bicykliske forbindelser og farmaceutiske sammensætninger, der indeholder dem - Google Patents

Neurobeskyttende bicykliske forbindelser og farmaceutiske sammensætninger, der indeholder dem Download PDF

Info

Publication number
DK1664050T3
DK1664050T3 DK04782733.2T DK04782733T DK1664050T3 DK 1664050 T3 DK1664050 T3 DK 1664050T3 DK 04782733 T DK04782733 T DK 04782733T DK 1664050 T3 DK1664050 T3 DK 1664050T3
Authority
DK
Denmark
Prior art keywords
substituted
aryl
heteroalkyl
alkyl
alkenyl
Prior art date
Application number
DK04782733.2T
Other languages
English (en)
Inventor
Margaret Anne Brimble
Jian Guan
Frank Sieg
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK1664050T3 publication Critical patent/DK1664050T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (8)

1. Forbindelse med formlen:
eller et farmaceutisk acceptabelt salt eller hydrat deraf, hvor X1 er valgt fra gruppen bestående af NR', O og S; X2 er valgt fra gruppen bestående af CH2, NR', O og S; R1 er valgt fra gruppen bestående af -OR', -SR', -NR'R', -NO2, -CN, -C(0)R', -C(0)0R', -C(0)NR'R', -C(NR')NR'R', trihalogenmethyl, halogen, alkyl, substitueret alkyl, heteroalkyl, substitueret heteroalkyl, alkenyl, substitueret alkenyl, al-kynyl, substitueret alkynyl, aryl, substitueret aryl, heteroaryl, substitueret hetero-aryl, arylalkyl, substitueret arylalkyl, heteroarylalkyl og substitueret heteroarylal-kyl; hvert R' er uafhængigt valgt fra gruppen bestående af -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl og heteroarylalkyl; R2, R3, R4 og R5 er uafhængigt valgt fra gruppen bestående af -H, -OR', -SR', -NR’R’, -NO2, -CN, -C(0)R\ -C(0)0R\ -C(0)NR'R', -C(NR')NR Ή’, trihalogenmethyl, halogen, alkyl, substitueret alkyl, heteroalkyl, substitueret heteroalkyl, alkenyl, substitueret alkenyl, alkynyl, substitueret alkynyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, arylalkyl, substitueret arylalkyl, heteroarylalkyl og substitueret heteroarylalkyl; hvert R1 er uafhængigt valgt fra gruppen bestående af -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl og heteroarylalkyl; eller R4 og R5 taget sammen er -CH2-(CH2)n-CH2-, hvor n er et heltal fra 0 til 6; eller R2 og R3 taget sammen er -CH2-(CH2)n-CH2-, hvor n er et heltal fra 0 til 6; med det forbehold, at når R1=methyl, og R2=R3=R4=H, så er R5 φ benzyl; hvor en substitueret alkyl-, substitueret heteroalkyl-, substitueret alkenyl-, substitueret alkynyl-, substitueret aryl-, substitueret heteroaryl- eller substitueret arylal-kylgruppe er en alkyl-, heteroalkyl-, alkenyl-, alkynyl-, aryl-, heteroaryl- eller aryl-alkylgruppe, hvor et eller flere af hydrogenatomerne er uafhængigt erstattet med en anden substituent, som indbefatter -R', -OR', -SR', -NR'R', -NO2, -CN, -C(O)-R', -C(0)0R', -C(0)NR'R', -C(NR’)NR'R', -NR'-C(NR')-OR', -NR'-C(NR')-SR', NR'-C(NR')-NR'R', trihalogenmethyl og halogen, hvor hvert R' uafhængigt er -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl eller heteroarylalkyl.
2. Forbindelse ifølge krav 1, hvor R1=methyl eller allyl.
3. Forbindelse ifølge krav 1, hvor R2=R3=methyl, og X2=S.
4. Forbindelse ifølge krav 1, hvor R1=allyl, R2=R3=R4=R5=H, X1=NH, og X2=-CFI2 (cyklisk G-2AllylP); eller hvor R1=methyl, R2=R3=H, R4 og R5 taget sammen er -CH2-(CH2)3-CH2-, X1=NH, og X2=CFl2 (cyklisk cyclohexyl-G2MeP); eller hvor R1=methyl, R2=R3=H, R4 og R5 taget sammen er -CH2-(CH2)2-CH2-, X1=NH, og X2=CFl2 (cyklisk cyclopentyl-G2MeP).
5. Farmaceutisk sammensætning, som omfatter en forbindelse ifølge et hvilket som helst af de foregående krav og en farmaceutisk acceptabel excipiens.
6. En eller flere forbindelser ifølge et hvilket som helst af kravene 1 -4 til anvendelse til beskyttelse af neuroner, som ellers vil degenerere eller dø som følge af en skade eller en sygdom.
7. En eller flere forbindelser til anvendelse ifølge krav 6, hvor sygdommen er kendetegnet ved apoptotisk neurondød, nekrotisk neuroncelledød, neuroncelle-degenerering, eller hvor skaden resulterer i nekrotisk neuroncelledød, apoptotisk neuroncelledød eller neuroncelledegenerering.
8. En eller flere forbindelser til anvendelse ifølge krav 6, hvor forbindelsen er valgt blandt cyklisk G-2AllylP, cyklisk cyclohexyl-G-2MeP og cyklisk cyclopentyl-G-2MeP.
DK04782733.2T 2003-09-03 2004-08-31 Neurobeskyttende bicykliske forbindelser og farmaceutiske sammensætninger, der indeholder dem DK1664050T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49995603P 2003-09-03 2003-09-03
PCT/US2004/028308 WO2005023815A2 (en) 2003-09-03 2004-08-31 Neuroprotective bicyclic compounds and methods for their use

Publications (1)

Publication Number Publication Date
DK1664050T3 true DK1664050T3 (da) 2016-03-07

Family

ID=34272894

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04782733.2T DK1664050T3 (da) 2003-09-03 2004-08-31 Neurobeskyttende bicykliske forbindelser og farmaceutiske sammensætninger, der indeholder dem

Country Status (9)

Country Link
US (2) US8067425B2 (da)
EP (1) EP1664050B1 (da)
JP (1) JP4842817B2 (da)
DK (1) DK1664050T3 (da)
ES (1) ES2564803T3 (da)
HU (1) HUE028528T2 (da)
PL (1) PL1664050T3 (da)
SI (1) SI1664050T1 (da)
WO (1) WO2005023815A2 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7485630B2 (en) * 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
KR20170038128A (ko) 2003-05-15 2017-04-05 앰피오 파마슈티컬스 인코퍼레이티드 Ｔ-세포 매개성 질환의 치료 방법
WO2008063311A2 (en) * 2006-10-11 2008-05-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8519127B2 (en) * 2003-09-03 2013-08-27 Mike John Bickerdike Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
US8217047B2 (en) * 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
EA028343B1 (ru) 2011-10-10 2017-11-30 Ампио Фармасьютикалз, Инк. Лечение дегенеративного заболевания сустава
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
CA2900335C (en) * 2012-10-22 2021-10-26 City Of Hope Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2015010937A (es) 2013-03-15 2015-10-29 Ampio Pharmaceuticals Inc Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas.
PT3024463T (pt) * 2013-07-25 2020-06-30 Neuren Pharmaceuticals Ltd Compostos bicíclicos neuroprotetores e métodos para a sua utilização no tratamento de distúrbios do espectro do autismo e distúrbios do neurodesenvolvimento
WO2016028790A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
TWI733817B (zh) * 2016-05-26 2021-07-21 日商阿明諾股份有限公司 睡眠改善劑
JP7088912B2 (ja) 2016-09-15 2022-06-21 シティ・オブ・ホープ ジチオｅｔｐ誘導体
US11590141B2 (en) 2018-03-16 2023-02-28 Scent Science International Inc. Prophylactic or therapeutic agent for hypoxic injury, ischemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent
BR112020023252A2 (pt) 2018-05-15 2021-02-23 Lloyd Hung Loi Tran composição do agente terapêutico e método de uso para tratamento de deficiência cognitiva leve, depressão e distúrbios psicológicos.
BR112022007636A2 (pt) 2019-10-22 2022-07-12 Neuren Pharmaceuticals Ltd Compostos bicíclicos e métodos para seus usos no tratamento da síndrome de pitt-hopkins
IL305132A (en) * 2021-02-12 2023-10-01 Neuren Pharmaceuticals Ltd Preparations for the treatment of the Prader-Willi phenomenon
JP2024545685A (ja) * 2021-12-17 2024-12-10 ザ シージーピー ラボ リミテッド Ｃｇｐの動物、真菌及び海洋供給源、並びに疾患管理のための、並びに非神経学的及び／又は神経学的状態の治療のための増大したｃｇｐ濃度
BE1032058B1 (nl) * 2023-10-26 2025-10-02 Rousselot Bv Cyclische analoog van glycine-proline voor gebruik bij de preventie en/of behandeling van fibrose

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469006A (de) * 1965-07-07 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer synthetischer Alkaloide
EP0626174A3 (en) * 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Method and composition for the prophylaxis and / or treatment of underactive organs.
US7202279B1 (en) * 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
AU2002340465A1 (en) * 2001-11-09 2003-05-19 Neuronz Biosciences, Inc. Cyclo(prolyl-glycine) and methods of use to treat neural disorders
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
WO2003041655A2 (en) 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US7485630B2 (en) 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use

Also Published As

Publication number Publication date
US8067425B2 (en) 2011-11-29
EP1664050B1 (en) 2015-12-09
WO2005023815A2 (en) 2005-03-17
ES2564803T3 (es) 2016-03-29
PL1664050T3 (pl) 2016-08-31
JP2007504235A (ja) 2007-03-01
US20060258663A1 (en) 2006-11-16
US20070197511A1 (en) 2007-08-23
WO2005023815A3 (en) 2005-07-21
JP4842817B2 (ja) 2011-12-21
US7776876B2 (en) 2010-08-17
HUE028528T2 (en) 2016-12-28
EP1664050A2 (en) 2006-06-07
SI1664050T1 (sl) 2016-04-29

Similar Documents

Publication Publication Date Title
DK1664050T3 (da) Neurobeskyttende bicykliske forbindelser og farmaceutiske sammensætninger, der indeholder dem
CA2790070C (en) Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
US8013170B2 (en) Substituted pyrrolo[1,2-d][1,4]-diazonines and treatment of brain damage
CN102159578B (zh) 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
AU2867899A (en) Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
US9119851B2 (en) Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals
US7863304B2 (en) Analogs of glycyl-prolyl-glutamate
US8519127B2 (en) Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
WO2006127702A2 (en) Analogs of glycyl-prolyl-glutamate
US20250367192A1 (en) Bicyclic compounds and methods for their use in treating pitt hopkins syndrome
US20090263334A1 (en) Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals
US6747042B2 (en) N-heterocyclic derivatives